Improved compounds for treatment of cancer and other estrogen related diseases.
Cardiovascular diseases and cancer are the leading causes of death in the U.S., accounting for almost 50% of all deaths (as of 2005). Many types of cancers are estrogen sensitive (e.g. breast, colon, ovarian, prostate, etc.). Furthermore, estrogen is also related to cardiovascular health, cognitive function and other conditions. Therefore, a compound which will act as an estrogen-receptor modulator may offer a treatment to these conditions. Current modulators show success but may also cause undesirable side-effects. The present invention utilizes compounds which exhibit a potent inhibitory effect on cancer cells, and may also prevent other diseases.
Isoflavones act as selective estrogen-receptor modulators, which are a class of medication that affects the estrogen receptor. Their action is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues. The present invention relates to novel isoflavone derivatives that exhibit more potent inhibitory activity on cancer cell growth than the parent isoflavones as was shown in relevant animal models. Furthermore, the novel derivatives may be administered together with cytotoxic drugs, leading to reduced side effects.